THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who we...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2020-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who were followed up at the V.A. Nasonova Research Institute of Rheumatology in 2011–2019. All the patients showed a severe course of AS of high clinical and laboratory activities, extra-articular manifestations, and inefficacy of three or more BAs. All the patients share the following symptoms: male gender, early onset of disease, high clinical and laboratory activities, and extra-articular manifestations, such as uveitis and psoriasis. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |